대장암 검진 시장 - 예측(2026-2031년)

The colorectal cancer screening market, growing at a 4.3% CAGR, is expected to grow to USD 20.329 billion in 2031 from USD 15.794 billion in 2025.

The colorectal cancer (CRC) screening market is a critical segment within the global in-vitro diagnostics and preventive healthcare landscape, focused on the detection of precancerous polyps and early-stage malignancies in the colon and rectum. Screening is paramount, as CRC typically develops slowly from adenomatous polyps, providing a significant window for interception and prevention. The market encompasses a range of modalities, including stool-based tests (fecal immunochemical tests, multitarget stool DNA tests), direct visualization techniques (colonoscopy, sigmoidoscopy, capsule endoscopy), and emerging blood-based assays. Market growth is driven by a powerful combination of rising disease burden, demographic shifts, and increasing efforts to improve screening accessibility and adherence.

Primary Market Growth Drivers

The expansion of the market is fundamentally linked to the rising global prevalence and burden of colorectal cancer. CRC remains one of the most commonly diagnosed cancers worldwide. The increasing incidence, particularly notable in younger age cohorts and in regions undergoing lifestyle transitions, underscores the urgent need for scalable screening programs. This epidemiological trend creates a sustained and growing addressable population for screening tests and procedures.

This burden is exacerbated by well-established and pervasive modifiable risk factors. Key lifestyle drivers include sedentary behavior, dietary patterns low in fiber and high in processed foods, obesity, and tobacco use. The global increase in these risk factors, linked to urbanization and changing socio-economic conditions, contributes to a higher population-wide risk profile, further justifying and necessitating broad screening initiatives.

A paramount demographic driver is the global aging of the population. While CRC incidence is rising in younger adults, the risk escalates significantly after age 50. The expanding demographic of adults over 50, particularly in developed economies, represents the core target population for organized screening programs. This demographic shift ensures a large and growing pool of individuals for whom screening is clinically recommended, directly driving test volumes.

Furthermore, increasing awareness and structured public health initiatives are critical catalysts. Government-led campaigns, professional society guidelines, and advocacy work have elevated public and clinical understanding of CRC as a preventable disease. The lowering of recommended screening initiation age to 45 in key guidelines, such as those from the U.S. Preventive Services Task Force, has expanded the eligible population. These efforts aim to overcome barriers of awareness and stigma, directly translating into higher screening participation rates.

Market Segmentation and Evolving Modalities

The market is characterized by a multi-modal approach, each with distinct advantages catering to different preferences and healthcare system resources. Stool-based tests, particularly fecal immunochemical tests (FIT), are widely used for population-based screening due to their non-invasiveness, low cost, and ease of use. Multitarget stool DNA tests (e.g., Cologuard) offer higher sensitivity for detecting advanced lesions, representing a premium non-invasive option. Colonoscopy remains the gold standard diagnostic and therapeutic procedure, allowing for both detection and immediate polyp removal. Innovation is focused on improving the accuracy and user-friendliness of non-invasive tests and enhancing the experience and efficiency of endoscopic procedures.

Geographical Outlook: North American Market Strength

North America is expected to maintain a significant share of the global colorectal cancer screening market. This position is supported by a mature screening infrastructure, high awareness levels among both providers and the public, well-established reimbursement pathways for multiple screening modalities, and a high prevalence of risk factors. The presence of leading diagnostic companies and a proactive regulatory environment for novel tests further consolidates the region's role as a primary market for innovation and adoption.

Competitive Landscape and Strategic Focus

The competitive landscape includes large, diversified diagnostic corporations, specialized molecular diagnostics companies, and medical device firms. Competition centers on test performance characteristics (sensitivity, specificity), ease of use, cost-effectiveness, and integration into clinical workflows. Strategic innovation is directed toward several key areas:

• Blood-Based Liquid Biopsies: Developing minimally invasive blood tests that detect circulating tumor DNA (ctDNA) or other biomarkers associated with CRC, potentially improving compliance by offering a simple blood draw.
• Enhanced Stool Tests: Improving the sensitivity of non-invasive tests for early-stage cancer and advanced adenomas while maintaining specificity to reduce false positives.
• Endoscopic Technology: Advancing imaging capabilities (e.g., high-definition, virtual chromoendoscopy) and artificial intelligence tools to improve adenoma detection rates during colonoscopy.
• Digital Engagement: Utilizing digital platforms and patient navigation services to increase screening initiation and completion rates, particularly in underserved populations.

Future Trajectory and Strategic Considerations

The colorectal cancer screening market is poised for continued growth, propelled by demographic inevitability and the strong clinical consensus on the value of early detection. Future evolution will be shaped by the pursuit of higher screening participation rates through more acceptable and accessible tests, and the move towards risk-stratified screening approaches that personalize recommendations based on genetic, familial, and lifestyle factors.

For industry participants, strategic success will depend on generating robust clinical evidence to support new technologies in guidelines, demonstrating cost-effectiveness to payers, and forming partnerships with health systems and public health organizations to implement integrated screening pathways. Navigating diverse international reimbursement landscapes and addressing health equity in screening access will also be critical challenges. As a cornerstone of cancer prevention, the CRC screening market's growth is inextricably linked to the global public health mission of reducing cancer mortality through proactive, evidence-based intervention.

Key Benefits of this Report:

• Insightful Analysis: Gain detailed market insights covering major as well as emerging geographical regions, focusing on customer segments, government policies and socio-economic factors, consumer preferences, industry verticals, and other sub-segments.
• Competitive Landscape: Understand the strategic maneuvers employed by key players globally to understand possible market penetration with the correct strategy.
• Market Drivers & Future Trends: Explore the dynamic factors and pivotal market trends and how they will shape future market developments.
• Actionable Recommendations: Utilize the insights to exercise strategic decisions to uncover new business streams and revenues in a dynamic environment.
• Caters to a Wide Audience: Beneficial and cost-effective for startups, research institutions, consultants, SMEs, and large enterprises.

What do businesses use our reports for?

Industry and Market Insights, Opportunity Assessment, Product Demand Forecasting, Market Entry Strategy, Geographical Expansion, Capital Investment Decisions, Regulatory Framework & Implications, New Product Development, Competitive Intelligence

Report Coverage:

• Historical data from 2021 to 2025 & forecast data from 2026 to 2031
• Growth Opportunities, Challenges, Supply Chain Outlook, Regulatory Framework, and Trend Analysis
• Competitive Positioning, Strategies, and Market Share Analysis
• Revenue Growth and Forecast Assessment of segments and regions including countries
• Company Profiling (Strategies, Products, Financial Information, and Key Developments among others.)

Colorectal Cancer Screening Market Segmentation

• By Screening Test
• Flexible Sigmoidoscopy
• Stool-based Tests
• CT Colonography
• Colonoscopy
• Others
• By End-User
• Independent Diagnostic Labs
• Hospitals
• Others
• By Geography
• North America
• USA
• Canada
• Mexico
• South America
• Brazil
• Argentina
• Others
• Europe
• Germany
• France
• United Kingdom
• Spain
• Others
• Middle East and Africa
• Saudi Arabia
• UAE
• Others
• Asia Pacific
• China
• India
• Japan
• South Korea
• Indonesia
• Thailand
• Others

TABLE OF CONTENTS

1. EXECUTIVE SUMMARY

2. MARKET SNAPSHOT

• 2.1. Market Overview
• 2.2. Market Definition
• 2.3. Scope of the Study
• 2.4. Market Segmentation

3. BUSINESS LANDSCAPE

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities
• 3.4. Porter's Five Forces Analysis
• 3.5. Industry Value Chain Analysis
• 3.6. Policies and Regulations
• 3.7. Strategic Recommendations

4. TECHNOLOGICAL OUTLOOK

5. COLORECTAL CANCER SCREENING MARKET BY SCREENING TEST

• 5.1. Introduction
• 5.2. Flexible Sigmoidoscopy
• 5.3. Stool-based Tests
• 5.4. CT Colonography
• 5.5. Colonoscopy
• 5.6. Others

6. COLORECTAL CANCER SCREENING MARKET BY END-USER

• 6.1. Introduction
• 6.2. Independent Diagnostic Labs
• 6.3. Hospitals
• 6.4. Others

7. COLORECTAL CANCER SCREENING MARKET BY GEOGRAPHY

• 7.1. Introduction
• 7.2. North America
  • 7.2.1. USA
  • 7.2.2. Canada
  • 7.2.3. Mexico
• 7.3. South America
  • 7.3.1. Brazil
  • 7.3.2. Argentina
  • 7.3.3. Others
• 7.4. Europe
  • 7.4.1. Germany
  • 7.4.2. France
  • 7.4.3. United Kingdom
  • 7.4.4. Spain
  • 7.4.5. Others
• 7.5. Middle East and Africa
  • 7.5.1. Saudi Arabia
  • 7.5.2. UAE
  • 7.5.3. Others
• 7.6. Asia Pacific
  • 7.6.1. China
  • 7.6.2. India
  • 7.6.3. Japan
  • 7.6.4. South Korea
  • 7.6.5. Indonesia
  • 7.6.6. Thailand
  • 7.6.7. Others

8. COMPETITIVE ENVIRONMENT AND ANALYSIS

• 8.1. Major Players and Strategy Analysis
• 8.2. Market Share Analysis
• 8.3. Mergers, Acquisitions, Agreements, and Collaborations
• 8.4. Competitive Dashboard

9. COMPANY PROFILES

• 9.1. Eiken Chemical Co. Ltd
• 9.2. Epigenomics Inc.
• 9.3. Exact Sciences Corporation
• 9.4. Polymedco Inc
• 9.5. Hemosure Inc.
• 9.6. F. Hoffmann-La Roche AG
• 9.7. QuidelOrtho Corporation
• 9.8. Siemens Healthineers AG
• 9.9. Sysmex Corporation
• 9.10. Olympus Corporation

10. APPENDIX

• 10.1. Currency
• 10.2. Assumptions
• 10.3. Base and Forecast Years Timeline
• 10.4. Key Benefits for the Stakeholders
• 10.5. Research Methodology
• 10.6. Abbreviations